Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Share-based Compensation (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Share-based Compensation data on record, last reported at $15.7 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 31.7% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $64.7 million, up 52.24%, while the annual FY2025 figure was $64.7 million, 52.24% up from the prior year.
  • Share-based Compensation reached $15.7 million in Q4 2025 per TGTX's latest filing, down from $17.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $36.6 million in Q4 2022 and bottomed at -$975000.0 in Q2 2022.
  • Average Share-based Compensation over 5 years is $12.6 million, with a median of $12.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: tumbled 105.98% in 2022, then surged 1382.05% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $14.4 million in 2021, then surged by 154.36% to $36.6 million in 2022, then crashed by 74.33% to $9.4 million in 2023, then rose by 26.87% to $11.9 million in 2024, then skyrocketed by 31.7% to $15.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $15.7 million in Q4 2025, $17.6 million in Q3 2025, and $16.4 million in Q2 2025.